Abiopharma

🔍 Carll Thomas Wayne (Executive)

Company: AstroNova, Inc. (ALOT)

Report Date: 2026-08-26

Detailed Transactions and Holdings:

• Sold 33,952 shares of Common Stock at $29.0 per share (Direct)
  Date: 2026-08-26 | Code: D | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1
• Sold 17,500 shares of Stock Option (Right to Purchase) at $18.25 per share (Derivative)
  Date: 2026-08-26 | Code: D | Expires: 2028-06-04 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2
• Sold 524 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-26 | Code: D | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F3, F3
• Sold 2,799 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-26 | Code: D | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F4, F4
• Sold 43,591 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-26 | Code: D | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F5, F5
• Sold 4,590 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-26 | Code: D | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F6, F6
• Sold 47 shares of Performance-Based Restricted Stock Units (Derivative)
  Date: 2026-08-26 | Code: D | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F7, F7

Footnotes:

• F1: Disposed of pursuant to that certain Agreement and Plan of Merger, dated as of June 16, 2026, by and among AstroNova, Inc. (the "Company"), Orion Merger Parent, Inc. ("Parent"), and Orion MergerCo X, Inc., a wholly owned subsidiary of Parent (as it may be amended from time to time, the "Merger Agreement").
• F2: Stock Option originally granted on June 4, 2018, which became fully vested on June 4, 2021, and was cancelled on the Transaction Date as provided for in the Merger Agreement in exchange for an aggregate cash payment of $188,125, representing an amount equal to the product of: (i) the aggregate number of shares of the Company's common stock, par value $0.05 per share (the "Common Stock") subject to such Stock Option multiplied by (ii) the excess, if any, of $29.00 (the "Merger Consideration") over the per share exercise price under such Stock Option.
• F3: Restricted Stock Units originally granted on June 10, 2024, which became fully vested and were cancelled on the Transaction Date as provided for in the Merger Agreement in exchange for an aggregate cash payment of $15,196, representing an amount equal to the number of shares of Common Stock underlying such Restricted Stock Units multiplied by the Merger Consideration.
• F4: Restricted Stock Units originally granted on April 14, 2025, which became fully vested and were cancelled on the Transaction Date as provided for in the Merger Agreement in exchange for an aggregate cash payment of $81,171, representing an amount equal to the number of shares of Common Stock underlying such Restricted Stock Units multiplied by the Merger Consideration.
• F5: Restricted Stock Units originally granted on August 15, 2025, which became fully vested and were cancelled on the Transaction Date as provided for in the Merger Agreement in exchange for an aggregate cash payment of $1,264,139, representing an amount equal to the number of shares of Common Stock underlying such Restricted Stock Units multiplied by the Merger Consideration.
• F6: Restricted Stock Units originally granted on February 26, 2026, which became fully vested and were cancelled on the Transaction Date as provided for in the Merger Agreement in exchange for an aggregate cash payment of $133,110, representing an amount equal to the number of shares of Common Stock underlying such Restricted Stock Units multiplied by the Merger Consideration.
• F7: Earned portion of Performance-Based Restricted Stock Units originally granted on April 18, 2022, which became fully vested and were cancelled on the Transaction Date as provided for in the Merger Agreement in exchange for an aggregate cash payment of $1,363, representing an amount equal to the number of shares of Common Stock determined to be subject to the earned and vested portion of the Performance-Based Restricted Stock Units multiplied by the Merger Consideration.